JPH0789854A - Carcinostatic agent - Google Patents

Abstract

PURPOSE:To obtain a carcinostatic agent effectively usable not only as an oral medicine but also as an injection, having no side effect, capable of being administered in a relatively large amount. CONSTITUTION:This carcinostatic agent comprises at least one compound selected from benzoic acid and its salts as an active ingredient.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to an anticancer drug which can be used without side effects.

[0002]

2. Description of the Related Art Conventionally, various studies have been made on benzaldehyde derivatives as anticancer agents. This is because benzaldehyde, which is an organic solvent with strong stimulability, cannot be used as a drug, but it can be used by making it a water-soluble solid derivative, and its drug effect can be expected. However, such a derivative cannot exert its medicinal effect unless the binding site is decomposed in the patient's body. Therefore, not only is it uneconomical, but there is a limit in usage and dosage. On the other hand, the inventor of the present invention administered a vitamin B ₁ derivative (biotamine from Sankyo Yakuhin Co., Ltd.) to cancer patients and confirmed its efficacy in several tens of cases.
It is considered that there is an effect because it hydrolyzes when absorbed from the intestinal tract and carbonylbenzene is released.

[0003]

In the administration of the above-mentioned benzaldehyde derivative, hydrolysis in the body is necessary to obtain the drug effect. Therefore, even if a large dose is administered, the dose can be reduced only within the limit of hydrolytic degradation. One cannot expect a proportional medicinal effect. Therefore, it cannot be expected to have an effect on the severely ill. Therefore, an object of the present invention is to provide a carcinostatic agent which does not require hydrolysis and can be effectively used not only for oral administration but also as an injectable drug and can be administered in a relatively large amount without side effects.

[0004]

Means for Solving the Problems The present inventor has focused on benzoic acid in which active hydrogen of benzaldehyde, which has been widely studied as an anti-cancer agent, is replaced with a hydroxyl group, and thought that it has a medicinal effect, completed.

The anti-cancer agent of the present invention contains at least one compound selected from benzoic acid and salts of benzoic acid as an active ingredient. In both cases of oral administration and injection, the active ingredient such as benzoic acid is 0%. A remarkable medicinal effect is observed by administering about 0.5 to 3 g / day.

The carcinostatic agent of the present invention may be formed into a liquid drug in which an active ingredient such as benzoic acid is mixed with a syrup, or a tablet using a powder carrier, or may be dissolved in Ringer's solution. And may be formed into an injection solution.

The benzoic acid used in the present invention is added to foods as a preservative, and Na benzoate is known to be used as an internal drug for acute rheumatoid arthritis because it has an antipyretic effect. Can be used without toxicity and side effects. It should be noted that other water-soluble and non-toxic salts such as K benzoate can also be used.

[0008]

【Example】

Example 1 A precancerous patient with liver cancer (male, 62 years old) was orally administered at a rate of 1 g of Na benzoate-20 cc of an aqueous solution of Na benzoate mixed with a syrup. In addition,
The drug efficacy was confirmed above and below the tumor marker. The tumor marker for liver cancer is α-fetoprotein, with a normal limit of 20 ng /
ml. The changes in tumor markers before and after administration of Na benzoate were as follows. Date Tumor marker Administration of Na benzoate 2 8 17 102.2 None 4 9 21 197.2 〃 10 13 116.1 〃 11 22 194.9 〃 12 17 Start administration 1 g / day 5 1 6 155.6 〃 3 4 76.5 〃 5 12 55.8 〃

Example 2 A patient (female, 30 years old) with a precancerous condition of stomach cancer was orally administered with 1 g of Na benzoate per day at a ratio of 20 cc of an aqueous solution of Na benzoate mixed with a syrup. The drug efficacy was confirmed above and below the tumor marker. The tumor marker for gastric cancer is IAP (immunosuppressive acid protein), and the normal limit is 500 μg / ml. Date Tumor marker Administration of Na benzoate 4 4 27 573 None 11 2 664 〃 12 2 664 〃 12 24 673 〃 12 29 Start of administration 1 g / day 5 1 20 588 〃 3 3 18 580 〃 6 〃 4 6 6 28 28 〃 6 21 dosage 1.5 g / day 7 5 624 〃 7 19 dosage 2 g / day 8 2 706 8 16 dosage 3 g / day 9 13 627 〃

Example 3 Na benzoate was dissolved in Ringer's solution at a rate of 100 mg / cc to adjust the pH to 7.4. When this solution was intraperitoneally injected to a gastric cancer patient with liver metastasis at a rate of 2 cc / day to 10 cc / day, the appetite was recovered without causing side effects.

Example 4 A patient (female age 36) who is diagnosed as having gallbladder cancer based on echo, palpation and subjective symptoms although the tumor marker is normal, 1 g of Na benzoate / day-an aqueous solution of Na benzoate is a syrup. When administered orally in a ratio of 20 cc-, the polyp image by echo disappeared and subjective symptoms were improved in about 1 month. However, when the drug was discontinued there, a polyp image by an echo appeared again after about 2 months, and therefore, the drug of Na benzoate was restarted.

[0012]

The administration of the drug of the present invention can prevent the growth of malignant tumor without side effects and increase the patient's appetite. The tumor marker usually increases geometrically with the passage of time and date, but as shown in Examples 1 and 2, the increase is obviously suppressed by the administration of the agent of the present invention.

Claims (1)

[Claims] 1. An anticancer agent containing as an active ingredient at least one compound selected from benzoic acid and salts of benzoic acid.